TABLE 1.
Clinical and phenotypical attributes of K. oxytoca isolatesa
| Isolation site | Diagnosisb | N and/or Oc | Toxind | Country of isolatione |
|---|---|---|---|---|
| Stool (40) | AAHC (16), diarrhea/colitis of other causes (11), IBD (3), asymptomatic carrier (7), follow-up/AAHC (1), asymptomatic carrier/UTI (1), NA (1) | N (9), O (25), NA (6) | Positive (31), Negative (9) | JPN (1), USA (1), NED (2), AUT (30), ESP (1), HKG (3), GER (2) |
| Respiratory tract (21) | Nosocomial pneumonia/VAP (13), COPD (2), cystic fibrosis (1), pneumonia (2), pharyngitis (2), pneumothorax (1) | N (15), O (6) | Positive (3), Negative (18) | AUT (21) |
| Urinary tract (4) | UTI (4) | N (2), O (2) | Negative (4) | AUT (4) |
| Blood (2) | AAHC with bacteremia (1), bacteremia (1) | O (2) | Positive (1), Negative (1) | AUT (2) |
| Skin/mucous membranes (7) | DFS (4), CSSTI (2), oral abscess (1) | O (7) | Positive (4), Negative (3) | AUT (7) |
a
The number of isolates within a given category is shown in parentheses.
b
AAHC, antibiotic-associated hemorrhagic colitis; IBD, inflammatory bowel disease; UTI, urinary tract infection; VAP, ventilator-associated pneumonia; COPD, chronic obstructive pulmonary disease; DFS, diabetic foot syndrome; CSSTI, complicated skin and skin structure infection.
c
Isolates were classified as nosocomial (N) when infection occurred 48 h after hospitalization. O, outpatient; NA, information not available.
d
Cytotoxicity was assessed via an MTT-based cell culture assay (6).
e
JPN, Japan; NED, Netherlands; AUT, Austria; ESP, Spain; HKG, Hong Kong; GER, Germany.